Data / Drug companies / Asclemed USA Inc.
Asclemed USA Inc.: 116 products in the FDA NDC directory, labeler code 87063
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Asclemed USA Inc. (labeler code 87063) lists 116 products in the FDA National Drug Code Directory, covering 49 finished drugs by generic name. By type: 111 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 1, 2026.
The request: Watch Asclemed USA Inc. (FDA labeler code 87063): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 87063
- Products in commercial distribution
- 116
- Packages
- 553
- Finished drugs by generic name
- 49
- Prescription products
- 111
- Over the counter products
- 4
- Controlled substance products
- Schedule II 9, Schedule III 1, Schedule IV 9
- Flagged as original packager
- 1 of 1 products that carry the flag
- Started marketing in the last 12 months
- 5
- Products with a marketing end date set
- 1
- Earliest marketing start
- July 15, 1975
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 102 | 87.9% |
| Authorized generics (NDA) | 4 | 3.4% |
| Other unapproved drugs | 4 | 3.4% |
| Over the counter monograph drugs | 3 | 2.6% |
| New drug applications (NDA) | 2 | 1.7% |
| Biologics (BLA) | 1 | 0.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 111 | 95.7% |
| Over the counter drugs | 4 | 3.4% |
| Vaccines | 1 | 0.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 73 | 62.9% |
| Tablet, film coated | 13 | 11.2% |
| Capsule | 6 | 5.2% |
| Ointment | 3 | 2.6% |
| Capsule, delayed release | 3 | 2.6% |
| Cream | 2 | 1.7% |
| Injection, solution | 2 | 1.7% |
| Solution | 2 | 1.7% |
| Patch | 2 | 1.7% |
| Injection | 2 | 1.7% |
| Gel | 2 | 1.7% |
| Injection, suspension | 2 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Flucelvax | 87063-299 | Injection, suspension | Biologics (BLA) | July 1, 2026 |
| Terocin | 87063-195 | Patch | Over the counter monograph drugs | May 5, 2026 |
| New Terocin | 87063-194 | Lotion | Over the counter monograph drugs | May 5, 2026 |
| Marvona-25 SUIK | 87063-079 | Injection, solution | Other unapproved drugs | January 24, 2026 |
| Lidothol ES | 87063-323 | System | Other unapproved drugs | January 6, 2026 |
| Methocarbamol | 87063-135 | Tablet | Generic drugs (ANDA) | May 22, 2025 |
| Lidothol | 87063-218 | Gel | Other unapproved drugs | March 27, 2025 |
| Xiclofen | 87063-056 | Ointment | Other unapproved drugs | February 7, 2025 |
| Metoprolol tartrate | 87063-188 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Metoprolol tartrate | 87063-187 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Metoprolol tartrate | 87063-186 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Metoprolol tartrate | 87063-185 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Metoprolol tartrate | 87063-184 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Amoxicillin | 87063-058 | For suspension | Authorized generics (NDA) | April 1, 2024 |
| Diclofenac Sodium | 87063-223 | Solution | Generic drugs (ANDA) | February 19, 2024 |
| Levetiracetam | 87063-193 | Tablet | Generic drugs (ANDA) | May 1, 2023 |
| Levetiracetam | 87063-192 | Tablet | Generic drugs (ANDA) | May 1, 2023 |
| Levetiracetam | 87063-191 | Tablet | Generic drugs (ANDA) | May 1, 2023 |
| Levetiracetam | 87063-190 | Tablet | Generic drugs (ANDA) | May 1, 2023 |
| Ramelteon | 87063-189 | Tablet | Generic drugs (ANDA) | May 1, 2023 |
| Valacyclovir | 87063-350 | Tablet | Generic drugs (ANDA) | February 14, 2023 |
| Valacyclovir | 87063-349 | Tablet | Generic drugs (ANDA) | February 14, 2023 |
| Methocarbamol | 87063-040 | Tablet, film coated | Generic drugs (ANDA) | February 9, 2023 |
| Cevimeline hydrochloride | 87063-324 | Capsule | New drug applications (NDA) | January 3, 2023 |
| Ropinirole | 87063-201 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.